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A B S T R A C T
Remyelination is an endogenous process by which functional recovery of damaged neurons is achieved by re-
instating the myelin sheath around axons. Remyelination has been documented in multiple sclerosis (MS) lesions
and experimental models, although it is often incomplete or fails to aﬀect the integrity of the axon, thereby
leading to progressive disability. Microglia play a crucial role in the clearance of the myelin debris produced by
demyelination and in inﬂammation-dependent OPC activation, two processes necessary for remyelination to
occur. We show here that following corpus callosum demyelination in the TMEV-IDD viral murine model of MS,
there is spontaneous and partial remyelination that involves a temporal discordance between OPC mobilization
and microglia activation. Pharmacological treatment with the endocannabinoid 2-AG enhances the clearance of
myelin debris by microglia and OPC diﬀerentiation, resulting in complete remyelination and a thickening of the
myelin sheath. These results highlight the importance of targeting microglia during the repair processes in order
to enhance remyelination.
1. Introduction
In the adult CNS, the loss of myelin is characteristic of demyeli-
nating diseases like multiple sclerosis (MS), although it is often fol-
lowed by a spontaneous process of remyelination, whereby oligoden-
drocyte progenitor cells (OPCs) diﬀerentiate and synthesize myelin to
ensheath the exposed axons (Chari, 2007). A hallmark of the re-
myelination in MS is the so-called shadow plaques, where myelin
staining lies is interspersed between the demyelinated plaques and the
normal white matter (Prineas et al., 1993; Plemel et al., 2017). How-
ever, the myelin sheaths generated during remyelination are typically
shorter and thinner than those generated during normal development
(Blakemore, 1974; Ludwin and Maitland, 1984).
The remyelination of axons not only restores saltatory conduction
but it also favors neuronal survival (Chari and Blakemore, 2002; Nave,
2010). Therefore, strategies designed to enhance this endogenous me-
chanism of repair are likely to be neuroprotective, limiting the clinical
disability associated with degeneration in demyelinating diseases. Al-
though OPCs can be found in most chronically demyelinated MS le-
sions, they have become quiescent and are unable to diﬀerentiate
(Plemel et al., 2017), or their maturation is frozen in a premyelinating
state in which the oligodendrocytes contact and ensheath the axons but
without forming compact myelin (Chang et al., 2002). For remyelina-
tion to occur, the intrinsic factors in OPCs must be orchestrated with the
extrinsic signaling associated with OPC proliferation, migration and
diﬀerentiation, driving processes that include the inﬂammation-
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dependent activation of OPCs (Miron et al., 2011) and the clearance of
myelin debris by phagocytes (Kotter et al., 2005; Neumann et al., 2009;
Lampron et al., 2015).
Microglia are thought to be detrimental in MS given their role in
proinﬂammatory cytokine production, antigen presentation and auto-
immunity (Fife et al., 2000; Heppner et al., 2005; Ajami et al., 2011).
However, microglia may also have beneﬁcial eﬀects in remyelination
since these cells might be associated with OPC recruitment and the
phagocytosis of myelin debris during demyelination (Jurevics et al.,
2002; Olah et al., 2012). Experimental models of demyelination have
shown that the presence of myelin debris impairs CNS remyelination by
inhibiting OPC diﬀerentiation (Kotter et al., 2006) and that eﬃcient
clearance of myelin by microglia is required for remyelination to occur
(Lampron et al., 2015). Hence, microglia are pivotal cells in sponta-
neous CNS regeneration.
The Theiler’s induced demyelinating disease model (TMEV-IDD)
resembles MS pathogenesis in terms of inﬂammation, demyelination
and neurodegeneration (Mecha et al., 2013a; Oleszak et al., 2004;
Tsunoda and Fujinami, 2010). In this model, pharmacological treat-
ment with synthetic cannabinoids, phytocannabinoids and even en-
docannabinoids (eCBs) exerts beneﬁcial eﬀects, limiting inﬂammation
in the acute (Mestre et al., 2011; Mecha et al., 2013b, 2018) and
chronic phase of the disease (Arévalo-Martín et al., 2003; Croxford and
Miller 2003; Ortega-Gutiérrez et al., 2005; Feliú et al., 2015; Granja
et al., 2012). In particular, exogenous 2-AG treatment modulates the
neuroinﬂammatory response following TMEV infection (Mecha et al.,
2018) and it ameliorates the outcome of EAE (experimental auto-
immune encephalomyelitis; Lourbopoulos et al., 2011), a commonly
used model of MS. Similarly, the increased endogenous 2-AG tone as-
sociated with the inhibition of the MAGL enzyme (which drives 2-AG
degradation) exerts therapeutic eﬀects, promoting remyelination in the
spinal cord of TMEV-IDD mice (Feliú et al., 2017) and preventing de-
myelination in the EAE model (Bernal-Chico et al., 2015).
To study the mechanisms underlying spontaneous remyelination,
we have taken advantage of the preclinical phase of the TMEV-IDD
model where prominent demyelination is evident in the corpus cal-
losum 35 days post-infection (dpi). This demyelination is followed by a
spontaneous and incomplete process of remyelination at 60 dpi, which
is subsequently lost with progression into the chronic phase of the
disease (Mecha et al., 2013b). We found a temporal discordance be-
tween the OPC recruitment and microglial activation in the demyeli-
nated corpus callosum. In addition, the eCB synthesis and hydrolysis
machinery was diminished speciﬁcally in this area. Enhancing eCB tone
through continuous 2-AG delivery before the onset of spontaneous re-
myelination in TMEV-infected mice elicited a pro-regenerative response
that involves microglia activation, myelin debris phagocytosis en-
hancement, and OPC diﬀerentiation. Consequently, the myelin content
in the corpus callosum was restored and the g-ratio of remyelinated
axons decreased at 60 dpi. Indeed, 2-AG also improved the phagocytic
capacity of human and rodent microglia in vitro. These results highlight
the relevance of targeting microglia during remyelination to orchestrate
the clearance of myelin debris and OPC diﬀerentiation in order to
achieve endogenous CNS repair.
2. Materials & methods
2.1. Animals
TMEV-IDD susceptible SJL/J female mice were obtained from
Envigo and maintained under standard conditions. Four-to-six week-old
mice were intracerebrally inoculated in the right hemisphere with
2× 106 plaque forming units (pfu) of the Danieĺs strain of TMEV di-
luted in 30 µl of DMEM (Dulbecco’s Minimal Essential Medium) sup-
plemented with 10% fetal calf serum (FCS; Lledó et al., 1999), studying
3–6 animals per experimental group. Sham operated mice received only
30 µl of DMEM supplemented with 10% FCS. All experiments were
performed following the ARRIVE guidelines and in accordance with EU
(Directive 2010/63/EU) and National (Royal Decree 53/2013 BOE No.
34 and Comunidad de Madrid: ES 280790000184) guidelines. The
Ethics Committee on Animal Experimentation at the Instituto Cajal
(CSIC) approved all the procedures described in this study (protocol
number: 2013/03 CEEA-IC).
2.2. Pharmacological treatment
Mice were deeply anesthetized 28 days after TMEV infection and
osmotic pumps were inserted into a small pocket under the skin of the
back of the mice for subcutaneous delivery. Two models of Alzet pumps
were used to deliver 2-AG (3.5 mg/kg, Tocris Bioscience) or the vehicle
(50% DMSO/15% ethanol/35% PBS -phosphate buﬀered saline): model
1007D delivering 0.5 μl/h/ for 7 days; and model 1002 delivering
0.26 μl/h for 14 days. The pumps delivered their load over 7 days in the
case of 28–35 dpi treatments to analyze demyelination at day 35, or
over 14 days in the case of 28–42 dpi treatments to analyze re-
myelination at 42 or 60 dpi. In those mice maintained to 60 dpi, the
pumps were removed once the treatment had ﬁnished at 42 dpi.
2.3. Immunohistochemistry
Mice were anesthetized with pentobarbital (Doletal, 50mg/kg body
weight, intraperitoneally – i.p.) and perfused transcardially with 0.9%
saline. For immunohistochemistry studies, the brains were ﬁxed over-
night with 4% paraformaldehyde (PFA) in PBS and coronal vibratome
sections (50 μm thick: Leica Microsystems) were obtained from the ol-
factory bulb to the beginning of the hippocampus. Slices were collected
in cold De Olmos solution and stored at −20 °C. For im-
munohistochemistry, free-ﬂoating brain sections were washed three
times for 10min with PBS, incubated with PBS containing 0.1% Triton-
X100 (Merck Millipore) and blocked for 1 h at room temperature in
blocking buﬀer containing 0.1% Triton X-100 and 5% normal serum
(Vector Laboratories). The sections were then incubated overnight at
4 °C with primary antibodies against the following proteins: Arg-1
(1:50; sc-18351, Santa Cruz Biotechnology); CC1 (1:200; OP80,
Calbiochem), Iba-1 (1:1000; 019-19741, Wako); Myelin Basic Protein
(MBP, 1:500; MAB382, Millipore); NOS-II (1:50; 610329 BD
Transduction); Olig-2 (1:200; sc-48817, Santa Cruz Biotechnology); PLP
(1:500; ab105784, Abcam). On the following day the sections were
rinsed three times for 10min with PBS containing 0.1% Triton X-100
and then incubated for 1 h with an Alexa Fluor-conjugated (1:500,
Molecular Probes Inc) or biotinylated (Vector Laboratories) secondary
antibody. For immunoﬂuorescence, sections were rinsed three times for
10min with PBS and mounted. In the case of PLP immunostaining with
the chromogen 3,3′ diaminobenzidine tetrahydrochloride (DAB: Sigma-
Aldrich), the sections were incubated for 1 h with a biotin-peroxidase
complex (Vector Laboratories, CA, USA) and ﬁnally with DAB. After
staining, the sections were dehydrated, cleared with xylene and cov-
erslipped. In all cases, the speciﬁcity of staining was conﬁrmed by
omitting the primary antibody.
2.4. RNA extraction, reverse transcription and RT-PCR
Mice were anesthetized with pentobarbital (Doletal, 50mg/kg body
weight, i.p.) and perfused transcardially with 0.9% saline. For in vivo
gene expression analysis, microdissection of the whole brain was per-
formed in ice-cold PBS to isolate the corpus callosum and adjacent
cerebral cortex. For in vitro studies, microglial cells were seeded at a
density of 100,000 cells/cm2 and lysed 6 h or 24 h after treatment with
2-AG (1 nM, Tocris Biosciences), a dose selected on the basis of our
previous studies (Mecha et al., 2015). In another subset of experiments,
microglia were treated with 2-AG (1 nM) for 24 h and lysed 6 h after the
addition of puriﬁed myelin (2 µg/mL). In each case, total RNA was
extracted using an RNeasy Lipid Tissue Mini Kit (Qiagen), treated with
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DNaseI (Promega) and 1 µg of this RNA was reverse transcribed using
the High capacity cDNA reverse transcription kit (Applied Biosystems).
The cDNA obtained was ampliﬁed by real-time PCR in a 7500 Real
Time PCR System (Applied Biosystems) with the Power SYBR® Green
reagent (Applied Biosystems). Gene expression was determined with
7500 Software v2.0.4 using ROX as a passive reference dye and re-
presented using the comparative Ct (cycle threshold) method. The ΔCt
was calculated by the diﬀerence between the Ct of each target gene and
the Ct of an artiﬁcial BestKeeper reference gene based on the Ct values
of two independent reference genes: RPS29/18S for in vivo analysis, and
36B4/RPS29 for in vitro studies (calculated using the BestKeeper©
Software, http://gene-quantiﬁcation.com/bestkeeper.html). We de-
termined the mRNA expression of the set of genes listed in Tables 1 and
2.
2.5. Myelin puriﬁcation and labeling
Myelin from 9-week old Wistar rat brains was isolated by sequential
centrifugation on a discontinuous sucrose gradient, as described
previously (Larocca and Norton, 2007). Brieﬂy, 2 g of rat brain tissue
was mechanically disaggregated in a 0.3 M sucrose solution, and
layered on a sucrose gradient composed of 0.3 M and 0.83M sucrose.
Sequential ultracentrifugation was performed at 4 °C using a Thermo
Scientiﬁc SureSpin 630 Rotor: 75,000 g, 30min; 75,000 g, 15 min; and
12,000 g, 15min. After two rounds of hypo-osmotic shock with a Tris-
HCl buﬀer solution, the myelin was resuspended in sodium carbonate
buﬀer (0.1M NaHCO3–Na2CO3, pH 9.4: Southwick et al., 1990) and
stored at −80 °C. The myelin protein content was determined by the
Bradford method, using bovine serum albumin as a standard, and 1mg/
ml myelin was labeled using CyTM3 (Mono-Reactive Dye Pack: Amer-
sham Biosciences) according to the manufacturer’s instructions, storing
the Cy3 conjugated myelin at 4 °C.
2.6. Human microglia cultures
Adult human brain microglia (Iba1+,> 95% purity) were obtained
from brain specimens resected from patients that underwent surgery to




Gene Accession # Forward primer 5′–3′ Reverse primer 5′–3′ Amplicon size
LAMP1 NM_012857.2 AGAAGGCTCCACGCATTTGA TGCAGCCTAACCACCATCAG 137
LAMP2 NM_017068.2 CAGGTGGTTTCCGTGTCTCG TCCAGTATGATGGCGCTTGAG 216
CD206 NM_001106123.2 GGTTGGATTGAGGCCTGAAA AACGTCCCTTTGTTTTGAACATC 66
MSR1 NM_001191939.1 TCGACTGGTTGATGGTAGCG ATCCTAGACTCCGGCAGACA 128
Scarb1 NM_031541.1 AGTAAAAAGGGCTCGCAGGA CTTCTGGGCCCTACAGCTTG 112
SIRP1a NM_013016.2 ACCCAGATCCAGGACACAAA GTGGACCATGTCCAGGTCAG 186
TREM2 NM_001106884.1 CCACGTGTTTGTCCTGTTGC CAGTGCCTCAAGGCGTCATA 120
36B4 NM_022402.2 TTCCCACTGGCTGAAAAGGT CGCAGCCGCAAATGC 60




Gene Accession # Forward primer 5′-3′ Reverse primer 5′-3′ Amplicon size
Arg1 NM_007482.3 ATGGAAGAGACCTTCAGCTAG GCTGTCTTCCCAAGAGTTGGG 224
CCL2 NM_011333.3 AGCAGGTGTCCCAAAGAAGCTGTA AAAGGTGCTGAAGACCTTAGGGCA 176
CD47 NM_010581.3 CACGGCCCCCTTTTGATTTC CTTCCAGCTGTGAGTCGTGA 137
IL1b NM_008361.4 TGGTGTGTGACGTTCCCATT TCCATTGAGGTGGAGAGCTTTC 110
IL10 NM_010548.2 TGAATTCCCTGGGTGAGAAGCTGA TGGCCTTGTAGACACCTTGGTCTT 147
LAMP1 NM_001317353.1 AGCATACCGGTGTGTCAGTG GGGAAGGTCCATCCTGTGTG 140
LAMP2 NM_010685.4 CTTAGCTTCTGGGATGCCCC TCATCCAGCGAACACTCCTG 164
CD206 NM_008625.2 GGTTGGATTGAGGCCTGAAA AACGTCCCTTTGTTTTGAACATC 66
MBP NM_001025259.2 ACACACGAGAACTACCCATTATGG AGAAATGGACTACTGGGTTTTCATCT 86
MSR1 NM_031195.2 CAGTGCTGTCTTCTTTACCAGC CTGAAGGGAGGGGCCATTTT 167
NOS-II NM_001313922.1 ACATTGATCTCCGTGACAGCC CCCTTCAATGGTTGGTACATG 158
Olig2 NM_016967.2 GACTCCCCCCTCCGTCTAAG CGCAGTAAAGCCCACGTTGT 147
PLP NM_001290562.1 NM_001290561.1 CCCACCCCTATCCGCTAGTT CAGGAAAAAAAGCACCATTGTG 71
SIRPα NM_007547.4 ACCCAGATCCAGGACACAAA GTGGACCATGTCCAGGTCAG 186
TNFα NM_013693.3 AGAGGCACTCCCCCAAAAGA CGATCACCCCGAAGTTCAGT 128
TREM2 NM_031254.3 GCACCTCCAGGAATCAAGAG GGGTCCAGTGAGGATCTGAA 200
18S NR_003278.3 ATGCTCTTAGCTGAGTGTCCCG ATTCCTAGCTGCGGTATCCAGG 101
RPS29 NM_009093.2 GCCGCGTCTGCTCCAA ACATGTTCAGCCCGTATTTGC 54
CXCL-12 NM_021704.3 CGGTTCTTCGAGAGCCACAT TCCTTTGGGCTGTTGTGCTT 192
Sema3A NM_001243072.1 CAGGCTGTGGAGTGGAGTG GCCTGATGCAACCTTCTGGA 175
Sema3F NM_001311151.1 TTAGACCCGTGTTGGTCAGC GGTCCATGCCCTGACAAGAA 182
DAGLa NM_198114.2 AGCCCTCCAAGCTCATCTCA TCAAGGGGCTCAATAAG 240
DAGLb NM_144915.3 AGCGACGACTTGGTGTTCC GCGTGAGATACAACGTCAGACT 85
MAGL NM_001166251.1 ACTTGGAAGTCCGACACCAC GGCGAACTCCACAGAATGTT 262
NAPE-PLD NM_178728.6 ATGGTGGAAATGGACGAGCTCATC TCATGTTTCTTCAAAAGCTCTATC 286
FAAH NM_010173.5 TGGGCCCTGCTCTGGATTTG CAGAGCTGGCGAATGAACGAC 340
IGF-1 NM_010512.5 GTGATCTGAGGAGACTGGAGATGTACT TGAGTCTTGGGCATGTCAGTGT 100
BDNF NM_007540.4 TCATACTTGGTTGCATGAAGG AGACCTCTCGAACCTGCCC 137
NM_001291058.1 TCTCTCATTTCCTTATGGACAGCTT ATTGATTCCACCGCCATGTAGTC 99
MFG-E8 NM_008594.2 GAATACATCTGCCAGTGCCC AGAACAACGGGAGGCTAGGTT 171
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previously (Nuttall et al., 2007). The tissues used were adjacent, but did
not comprise, the epileptic focus in cortical areas. This material was
used in accordance with the approval of the Research Ethics Board at
the University of Calgary. In brief, the brain tissue targeted for excision
was suctioned into a sterile bag retrieved with a Cavitron Ultrasonic
Aspirator. The tissue fragments, of less than 2mm3 in size, were im-
mersed within the sterile bag at room temperature (23 °C) by the saline
that was used during surgery to keep the brain moist. Upon completion
of the surgery, the sterile bag was transported within the hour at room
temperature to the tissue culture laboratory for processing. In brief, the
sterile bag content was transferred at room temperature into 50ml
tubes, removing the blood, meninges and clots by washing the tissue
several times with PBS, and letting the brain tissue settle between
washes. The content was transferred to a sterile 100ml glass bottle for
digestion with DNase (0.1 mg/ml) and 0.25% trypsin in PBS, and in-
cubated at 37 °C for 25min. Subsequently, FCS was added to inactivate
the trypsin, and the sample was ﬁltered through a sterile 130 µm mesh
and centrifuged at 1200 rpm for 10min. The sample was diluted in
21ml of PBS and laid over 9ml of Percoll in sterile 6–8 polycarbonate
ultra-centrifuge tubes. The sample was mixed with a pipette and cen-
trifuged at 15,000 rpm in a Beckman J2-21M centrifuge with no brakes
at 4 °C for 30min. The myelin was then removed by aspiration from the
upper layer, and the viable cell layer was recovered with a pipette and
diluted 1:1 in PBS. The cells were washed twice in Complete MEM and
recovered by centrifugation at 1200 rpm from 10min (MEM+0.2mM
Glutamine, 100 µg/ml Pen/Strep, 1X Non-essential amino acids, 1x
Sodium pyruvate, 0.1% Dextrose and inactivated 10% FCS). Finally, the
cells were suspended in medium, plated at 2×106 cells/ml in 5ml
uncoated T25 ﬂasks and incubated for two nights at 37 °C in an at-
mosphere of 5% CO2. The microglia adhered strongly to the ﬂask, while
the other cell types (principally oligodendrocyte precursor cells; neu-
rons do not survive the isolation procedure while astrocytes are lost in
the discarded Percoll fractions) remained in suspension or were only
loosely attached. After removing the ﬂoating cells, the ﬂasks were
washed and trypsinized to obtain the microglia, which were then plated
in poly-L-ornithine (0.01 mg/ml) coated 96-well plates at a density of
50,000 cells/100 μl medium. The cells were cultured for 3 days prior to
treatment and then exposed to 2-AG (1 nM) for 24 h after 1 h of star-
vation in DMEM. Subsequently, pH Rodo particles were added to the
culture media for 30min and the cells were washed with live imaging
buﬀer (Gibco). Calcein AM was then added to the medium and the cells
were analyzed with a Molecular Devices ImageXpress high-content
imaging system.
2.7. Rat microglia cultures
Primary microglia cell cultures from P0–P2 Wistar rats were pre-
pared as described previously (Correa et al., 2009; McCarthy and De
Vellis, 1980), with minor modiﬁcations (Mecha et al., in doi: https://
doi.org//10.1038/protex.2011.218, Open Nature Exchange protocol
only online). Puriﬁed microglia were plated at a density of
100,000 cells/cm2 for PCR analysis, or at 50,000 cells/cm2 for im-
munocytochemistry and phagocytosis assays. The cells were main-
tained for 3 days at 37 °C and in 5% CO2, in a deﬁned medium con-
taining 10% horse serum and 10% FCS, and they were incubated for 1 h
in serum-free DMEM prior to the pharmacological treatments. For RT-
PCR studies, 2-AG (1 nM: Tocris Bioscience) was applied to the micro-
glia cultures for 6 or 24 h. In another set of experiments, microglia were
stimulated with 2-AG for 24 h and then puriﬁed myelin was added to
the culture media for 6 h. In the case of the assay of myelin phagocy-
tosis, 2-AG and TGF-β (20 ng/ml, PeproTech, Inc, UK) were applied for
24 h before the addition of the puriﬁed myelin.
2.8. In vitro myelin phagocytosis and immunocytochemistry
Rat microglial cells were grown on poly-D-lysine (5 µg/mL) coated
glass coverslips and 1 h after serum starvation, they were exposed to 2-
AG (1 nM), TGFβ (20 ng/mL) or both for 24 h. After this period, the
microglia were washed with warm DMEM (37 °C) and exposed to 1 or
2 µg/mL puriﬁed myelin for 1 h. In a subset of experiments, myelin was
labeled with Cy3 prior to its addition to the microglia cultures, as de-
scribed previously. The cells were ﬁxed with 4% PFA for 20min and
permeabilized with 0.1% Triton X-100 in PBS. After blocking with 5%
normal goat serum (NGS), the microglial cells were incubated for 2 h at
room temperature with a rabbit antiserum against mouse Iba-1 (1:500;
019-19741, WAKO) and MBP (1:500; MAB382, Millipore) in order to
calculate the proportion of phagocytosing cells. After rinsing, glass
coverslips were incubated for 1 h at room temperature with Alexa
Fluor-conjugated antibodies (1:500, Molecular Probes, Inc), which were
then mounted on slides with Mowiol and kept in the dark at 4 °C until
they were analyzed on a laser scanning confocal microscope (Leica TCS-
SP5). Myelin phagocytosis was evaluated in vitro and expressed as the
percentage of phagocytic cells per ﬁeld, the total amount of myelin
phagocytosed within the cells and using an adaptation of the phago-
cytosis index described previously (see Natrajan et al. (2015)), which
relates Cy3 ﬂuorescence in the treated and control cells.
2.9. Immunoelectron microscopy and the g-Ratio
Mice were anesthetized deeply with pentobarbital (Doletal, 50mg/
kg body weight, i.p.), and perfused transcardially with 0.9% saline and
then, with a ﬁxative solution (2.5% PFA/2.5% glutaraldehyde). The
brain of each mouse was then post-ﬁxed in the same ﬁxative solution
for 40min, washed with phosphate buﬀer (0.1M), and sagittal vi-
bratome sections were obtained from the corpus callosum (150 μm
thick, Leica Microsystems). After washing the slices were incubated in
osmium tetroxide (2% OsO4 in 5.4% glucose/PB) for 1 h at room tem-
perature, and dehydrated in an increasing acetone gradient. The sam-
ples were then embedded in Spurr’s Resin (TAAB Lab Equipment
Limited) and polymerization was achieved after incubation at 65 °C for
48 h. Ultrathin sections (65–70 nm) were obtained on an ultra-
microtome (EM UC6; Leica, Graz, Austria), mounted on copper grids
(200 mesh) and then examined with a transmission electron microscope
(JEM-1200EX II: Jeol, Tokyo, Japan) operated at 80 kV. The images
were recorded with a SIS Mega-View III CCD camera and the ImageJ
software was used to evaluate the g-ratio of individual myelinated
axons, a measure of myelin thickness as a function of the axon dia-
meter. The g-ratio plug-in (http://gratio.eﬁl.de) was employed on
randomly selected axons in transverse sections of the corpus callosum
using semi-thin light micrographs from each mouse analyzed. We per-
formed measurements on a total of 100 selected axons per animal and
the cumulative g-ratios were calculated for each mouse by averaging all
the individual g-ratios.
2.10. Image processing and analysis
All confocal images were acquired on a Leica TCS SP5 confocal
microscope. For in vivo studies, individual images of 4–5 sections of the
corpus callosum (between bregma 1.10mm to−1.06 coordinates) from
at least 6 animals per group were analyzed. Immunostaining and cell
counts were quantiﬁed using Fiji software (designed by the National
Institutes of Health), evaluating the proportion of staining relative to
the total area in Sham animals and the total number of cells/mm2. In
the case of microglia that internalized MBP, orthogonal views were
captured in the z-direction in three diﬀerent areas from the mouse
corpus callosum using 40× objectives (with a 0.8 µm step size in the
confocal stacks) and analyzed with Imaris. The total number of Iba-1+
cells and the number of Iba-1+ cells with internalized myelin (MBP
staining inside the cell in the in vivo experiments or Cy3 staining inside
the cell in the in vitro procedures) were counted using the cell counter
plug-in of Image J. The MBP+ area inside the Iba-1+ cells was de-
termined using the Image J co-localization plug-in, analyzing at least 20
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microglial cells per section.
To determine the volume of MBP internalized by each microglial
cell in the corpus callosum, a three-dimensional image from each mi-
croglia cell was created using the Imaris software. First, a surface cor-
responding to Iba-1 staining was created and then, to remove staining
not at the microglia surface, a mask was created corresponding to the
MBP channel setting all the voxels beyond that to 0. Finally, we created
a second surface inside the microglial surface based on the mask of MBP
positive staining exclusively within the cell. The “Number of voxels”
ﬁlter was applied to each surface and the total volume of MBP inside
the microglia, as well as total volume of each microglial cell was cal-
culated for subsequent analysis. The volumes of MBP were quantiﬁed
within at least 30 microglial cells.
For in vitro analysis, 2 µm step size confocal stacks were captured in
the z-direction from 50 cells in 5 ﬁelds per experimental condition and
experiment, using 20× objectives on the same confocal microscope (5
independent experiments were performed). Myelin phagocytosis in vitro
was evaluated by determining the number of Iba-1+ cells and the
number of Iba-1+ cells with internalized myelin (MBP+) using the cell
counter plug-in in Image J. These parameters were determined in 50
cells from 5 ﬁelds per experimental condition and experiment (5 in-
dependent experiments were performed). In vitro myelin uptake was
determined after deﬁning the single cell perimeter as the Cy3 area in-
side the selected area, measured as the average immunoreactivity in the
red channel in the selected cell. The same threshold was set for all the
cells and all experimental conditions.
2.11. Statistical analysis
Bar graphs represent the mean ± SEM and the data in scattered
plots are expressed as the median ± range. GraphPad Prism software
version 5.0 for Windows and SPSS 22 software (IBM Corporation, USA)
were used for the statistical analysis. The normality of the data was
assessed with a Barlett’s test. The p values were obtained with a
Student’s two tailed t-test and one-way analysis of variance (ANOVA)
was used for multiple comparisons, followed by a Bonferroni post-hoc
test to determine the statistical signiﬁcance. Whenever normality was
not achieved, statistical signiﬁcance was determined with non-para-
metric tests (Kruskal-Wallis and post-hoc pair-wise comparisons with a
Mann-Whitney U test). Benjamini-Hochberg’s correction was applied to
control multiple testing in the in vivo RT-PCR data analysis, setting the
signiﬁcance threshold to 3% as adjusted P value. The analysis of cov-
ariance was used to analyze regression lines. The level of signiﬁcance
was set at *p adjusted ⩽0.03 for in vivo RT-PCR analysis, and *p⩽ 0.05
for the others; **p⩽ 0.01; and ***p⩽ 0.001.
3. Results
3.1. Corpus callosum demyelination mobilizes OPCs and microglia along
with reduced synthesis and degradation machinery of eCBs
From a therapeutic point of view, demyelination in the TMEV-IDD
mouse MS model has commonly been studied in the spinal cord and
related to the motor deﬁcits evident in these mice (Feliú et al., 2017).
Yet in the preclinical stage, demyelination can also be observed in non-
classical demyelinated structures like the brainstem, cerebral cortex
(Mecha et al., 2013a) and even, the corpus callosum (Mecha et al.,
2013b). Signiﬁcantly, this demyelination is followed by a spontaneous
and incomplete process of remyelination that declines in the chronic
phase of the disease. Here, we have focused on the corpus callosum as
one of the major white matter structures in the brain. Im-
munohistochemical analysis of MBP staining showed that demyelina-
tion was extensive 35 days after TMEV intracerebral infection, with a
loss of 95% of the area occupied by MBP compared to Sham mice
(Fig. 1a, b). This loss of MBP was accompanied by a signiﬁcant decrease
in mbp and plp mRNA, the two major myelin proteins in the CNS
(Fig. 1c). This marked demyelination was not associated with the loss of
mature oligodendrocytes, as no change in the number of CC1+ oligo-
dendrocytes was observed (Fig. 1d, e). Remarkably, more OPCs (Olig-
2+/CC1−) were found in the corpus callosum, which was probably
related to the mobilization and fast diﬀerentiation of OPCs into pre-
myelinating oligodendrocytes, as suggested by the diminished olig-2
gene expression (Fig. 1f).
The inﬂammatory milieu is a mediator of remyelination (Franklin
and Ffrench-Constant, 2008) and in the demyelinated corpus callosum,
while there were more Iba-1+ microglial cells, no change in the area
occupied by these cells was evident by immunohistochemistry (Fig. 1g,
h). When we analyzed the mRNA expression of inﬂammatory mediators
and chemokine genes, we found that demyelination did not alter the
expression of the pro-inﬂammatory cytokines tnf-α or il-1β, whereas the
expression of the anti-inﬂammatory cytokine il-10 (Fig. 1i) and that of
the chemokine ccl-2 increased. Conversely, there was a signiﬁcant
downregulation of cxcl-12, sema3A and sema3F expression (Fig. 1j). As
the eCB system is thought to be dysregulated in MS and in the EAE
murine model (Centonze et al., 2007), we studied the 2-AG and AEA
synthetic and degradation machinery in the corpus callosum by RT-
PCR. Surprisingly, the 2-AG and AEA synthesis and degradation ma-
chinery was dampened in this demyelinated structure (Fig. 1k), with
reduced expression of the main enzyme responsible for the synthesis of
2-AG (dagl-α diacylglycerol lipase-α) while the reduction in its hydro-
lysis enzyme did not reach statistical signiﬁcance (magl-mono-
acylglycerol lipase). The enzymes that account for the synthesis (nape-
pld) and degradation (faah) of AEA were both reduced. By contrast, the
expression of these enzymes did not change in the adjacent cerebral
cortex (Fig. S1), suggesting a speciﬁc reduction in the synthesis en-
zymes of the two major eCBs in demyelinated white matter lesions.
3.2. 2-AG modiﬁes microglia activation state in demyelinated corpus
callosum
Taking into account the reduced eCB synthesis machinery in the
demyelinated corpus callosum and to evaluate the potential inﬂuence
of eCBs on spontaneous remyelination, we administered 2-AG to TMEV
infected mice using subcutaneous mini-osmotic pumps that were im-
planted on day 28 pi to mediate its constant delivery. On day 35 pi,
7 days of 2-AG delivery did not modify the loss of MBP in the corpus
callosum (Fig. 2a), or the downregulation of mbp, plp and olig-2 gene
expression relative to the vehicle-treated TMEV mice (Fig. 2b). Ac-
cordingly, the number of mature oligodendrocytes and OPCs in the
demyelinated corpus callosum did not diﬀer between the two experi-
mental groups (Fig. 2c), although there were fewer OPCs in the ad-
jacent cortex in the animals that had been treated with the eCB (Fig.
S2). Remarkably, the immunostaining for Iba-1 was enhanced in the
mice administered 2-AG (Fig. 2d). While there was no diﬀerence in the
number of Iba-1+ microglia in the demyelinated corpus callosum of 2-
AG and vehicle-treated TMEV mice, the area occupied by these cells
was signiﬁcantly larger in the animals that received 2-AG (Fig. 2e),
probably due to the activation of microglia in the demyelinated corpus
callosum that was not signiﬁcant in the adjacent cortex (Fig. S2). The
signiﬁcant increase in the expression of the inﬂammatory markers tnf-α
and il-1β further suggested the activation of microglia in mice ad-
ministered 2-AG, although we also observed higher levels of il-10
(Fig. 2f). Moreover, we found an upregulation in the expression of cxcl-
12 and sema3FmRNA relative to the vehicle-treated mice (Fig. 2g, h). In
terms of the eCB machinery, RT-PCR analysis showed enhanced AEA
synthesis enzyme (nape-pld) with a tendency to increase faah expres-
sion, and no alteration to 2-AG synthesis or degradation enzymes
(Fig. 2i). No diﬀerences were found when the expression of in-
ﬂammatory mediators and enzymes related to eCB machinery was
analyzed in the adjacent cortex relative to TMEV-Vehicle mice (Fig. S2).
Our results suggest that exogenous administration of 2-AG partially
restores the eCB enzymes machinery expression in the demyelinated
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corpus callosum, and it also elicits the activation of microglial cells that
could aﬀect the ensuing remyelination.
At 42 dpi, a considerable increase in MBP staining was evident in
the corpus callosum of TMEV mice (Fig. 3a) relative to day 35 pi,
indicating the initiation of endogenous repair. When the area occupied
by MBP was analyzed, there was a signiﬁcant increase in TMEV mice
relative to 35 dpi, that was further enhanced following the adminis-
tration of 2-AG over the previous 14 days (Fig. 3b). The remyelination
(caption on next page)
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that underlies the increased MBP staining was accompanied by an in-
crease in the number of OPCs relative to 35 dpi (Figs. 3c and 2c). In-
deed, there was also a signiﬁcant increase in the number of OPCs in the
adjacent cortex (Fig. S3). At this time, the morphological changes re-
lated to activation of microglial cells in the corpus callosum were
prominent in vehicle and 2-AG treated mice (Fig. 3d), together with a
signiﬁcant increase in the area occupied by Iba-1, without aﬀecting the
total number of microglial cells relative to 35 dpi (Figs. 3e and 2e). This
increase in the area occupied by microglia at 42 dpi was also found in
the cerebral cortex, where 2-AG treatment diminished the reactivity of
these cells without modifying the increase in their number (Fig. S3).
The expression of the tnf-α gene was upregulated in both experimental
groups, whereas il-1β was only enhanced in the mice that received
vehicle and il-10 expression shows a tendency to increase in 2-AG
Fig. 1. Corpus callosum demyelination mobilizes OPCs and microglia along with reduced synthesis and degradation machinery of eCBs at 35 dpi. (a) MBP im-
munoﬂuorescence to measure the myelin content in the corpus callosum (CC) at 35 dpi, (b) data quantiﬁcation shows a prominent loss in MBP content in TMEV
infected mice; (c) RT-PCR analysis of MBP and PLP mRNAs shows a signiﬁcant reduction in the myelin protein synthetic machinery. (d) Olig-2/CC1 dual im-
munoﬂuorescence in the CC discriminates mature oligodendrocytes (Olig2+CC1+) and OPCs (Olig2+CC1−). (e) The quantiﬁcation of dual immunoﬂuorescence
highlights the increase in OPC number in TMEV mice, accompanied by a decrease in Olig-2 expression evident by RT-PCR (f). (g, h) Iba-1 staining in the demye-
linated CC shows no apparent changes in the activation of microglia with an increase in the number of these cells (h). The inﬂammatory milieu in the CC was
analyzed by RT-PCR, assessing the cytokines, tnf-α, il-1β and il-10 (i) the chemokines, ccl-2 and cxcl12 and the semaphorins, sema3A and sema3F (j). (k) Quantiﬁcation
of the expression of enzymes involved in the synthesis and degradation of 2-AG and AEA showing reduced dagl-α, nape-pld and faah gene expression following
demyelination. Each point represents the mean ± SEM from 5 to 7 mice per group: *p adjusted≤0.03; **p≤ 0.01; ***p≤ 0.001 vs. Sham mice. Scale bar: 25 μm (a,
d) and 50 μm (g).
Fig. 2. 2-AG administration modiﬁes microglia activation state in demyelinated corpus callosum at 35 dpi. No diﬀerences are found between 2-AG and Vehicle
treated TMEV mice in: (a) the proportion of MBP quantiﬁed by immunohistochemistry, (b) mbp, plp or Olig-2 mRNA analyzed by RT-PCR, or the number of mature
oligodendrocytes and OPCs (c). 2-AG treatment increases the Iba-1 staining in the CC evident by immunohistochemistry (d), showing an increase in the area occupied
by microglia with no change in the total number of microglial cells (e). RT-PCR analysis shows that 2-AG increases the levels of the cytokines tnf-α, IL-1β and IL-10 (f)
and the chemokine cxcl-12 (g) and sema3F (h) mRNAs, restoring the expression of the machinery involved in the synthesis of AEA without aﬀecting the 2-AG
metabolic enzymes (i). Each data point represents the mean ± SEM from 5 to 7 mice per group: #p adjusted≤0.03; ##p≤ 0.01 vs. TMEV+Veh. Scale bar: 50 μm.
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Fig. 3. 2-AG promotes endogenous remyelination at 42 dpi. Remyelination is evident in the CC at 42 dpi, as witnessed by MBP immunostaining when comparing
TMEV infected mice at 42 and 35 dpi (a). 2-AG further promotes the increase in the area occupied by MBP (b), without aﬀecting the total number of OPCs (c).
Microglial activation at 42 dpi is highlighted by Iba-1 immunoﬂuorescence (d), although no changes are found in the area occupied by microglia or in the total
number of cells by 2-AG (e). RT-PCR studies of the corpus callosum analyze the expression of the cytokines tnf-α, IL-1β and IL-10 (f), the chemokines, ccl-2 and cxcl12
and the semaphorins, sema3A and sema3F (g), enzymes involved in the synthesis and degradation of eCBs (h), and the growth factors igf-1 and bdnf (i). Each point
represents the mean ± SEM from 6 to 10 mice per group: *p adjusted≤0.03; **p≤ 0.01; ***p≤ 0.001 vs. Sham; ##p≤ 0.01; ###p≤ 0.001 vs. TMEV+Veh. Scale
bar: 25 μm (a), 10 μm (b).
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treated mice (Fig. 3f). This proﬁle was conﬁned to the remyelinating
corpus callosum, since no signiﬁcant changes were found in the ad-
jacent cortex (Fig. S4). Immunohistochemistry and RT-PCR for nos-II
and arg-1 in the corpus callosum was performed to further analyze the
inﬂammatory proﬁle of microglia, yet no diﬀerences were found be-
tween the two experimental groups (Fig. S5).
Chemokine expression was aﬀected by eCB treatment, with en-
hanced ccl-2 mRNA and reduced levels of sema3F in both groups
(42 dpi, TMEV+vehicle and TMEV+2-AG), while cxcl-12 was en-
hanced and sema3A partially restored in 2-AG treated mice (Fig. 3g).
Regarding eCB biosynthesis and inactivating machinery, RT-PCR ana-
lysis showed a general increase in the expression of the main synthesis
enzymes of 2-AG or AEA in both groups, whereas the hydrolysis en-
zymes were only upregulated in TMEV mice that received vehicle
(Fig. 3h), perhaps related to the endogenous process of remyelination.
In the adjacent cortex, non-signiﬁcant changes were observed in eCB
metabolic machinery expression following 2-AG treatment (Fig. S4). In
the corpus callosum (Fig. 3h), exogenous 2-AG administration did not
modify dagl-α or magl levels compared to the Sham mice, whereas dagl-
β was increased and the AEA synthesis enzyme nape-pld was upregu-
lated without aﬀecting the degradation enzyme faah. These changes
were probably due to adjustments in the eCB system related to the
continuous release of 2-AG by the miniosmotic pumps. The aforemen-
tioned changes were found in conjunction with increased expression of
igf-1 involved in CNS remyelination and repair, both in vehicle and 2-
AG treated mice, while exogenous 2-AG restored the expression of the
bdnf gene that was downregulated in vehicle-treated TMEV mice
(Fig. 3i).
3.3. 2-AG boosts myelin debris phagocytosis
Myelin debris has been related to the inhibition of OPC diﬀer-
entiation, impairing remyelination (Kotter et al., 2006). Given the
changes in microglial activation associated with demyelination in the
corpus callosum, we further studied the possible implication of these
cells in the phagocytosis of myelin debris. The expression of genes as-
sociated with myelin phagocytosis and the overall phagocytic ma-
chinery was analyzed by RT-PCR. One of the mechanisms by which
myelin downregulates its own phagocytosis is through the expression of
CD47 by myelin, and SIRPα by microglia and macrophages (Gitik et al.,
2011). In our experimental model of demyelination, this interaction
was diminished signiﬁcantly on day 35 pi compared to Sham mice
(Fig. 4a), suggesting a potential deﬁcit in the phagocytosis of myelin
debris by microglia and/or macrophages. However, no changes were
found when we compared sirpα/cd47 expression in mice administered
with the vehicle alone or with 2-AG. In terms of the expression of other
phagocytosis associated genes, we evaluated those implicated in the
general phagocytic machinery (cd206, msr1, cd68 and mgf-e8: Fig. 4b)
and in phagosome assembly (lamp1 and lamp2: Fig. 4c). These mole-
cules are upregulated in vitro, in conjunction with an enhanced capacity
of microglia to phagocytose myelin following IFNβ stimulation (Kocur
et al., 2015). In TMEV mice, we observed a tendency to downregulate
cd206 and a signiﬁcant reduction of mgf-e8mRNA expression compared
to the Sham mice, whereas 2-AG administration increased msr1 ex-
pression at 35 dpi. By contrast, there were no signiﬁcant changes on the
expression of cd68, lapm1 or lamp2. At 42 dpi sirpα/cd47 gene expres-
sion was restored to Sham levels in both experimental groups (Fig. 4d).
The expression of some of the genes involved in the general phagocytic
machinery was upregulated in the mice that received the vehicle alone,
cd206, cd68 and mgf.e8, although increased msr1 expression did not
achieve statistical signiﬁcance (Fig. 4e). In the case of the genes asso-
ciated with phagosome assembly, 2-AG treatment enhanced the ex-
pression of lamp-1 in comparison to the Sham mice (Fig. 4f). Although
our study is limited by the lack of proteins measurement, we underline
the increased gene expression of msr1 and lamp1 by 2-AG.
To assess speciﬁcally the phagocytosis of myelin debris by
microglia, we performed dual immunohistochemistry of MBP and Iba-1
in the corpus callosum, focusing on MBP proﬁles within microglia at 35
and 42 dpi highlighted in the orthogonal views of confocal stacks
(Fig. 5a, c). These confocal projections were used to study the pro-
portion of microglia with internalized MBP, which indicated that there
were no changes between the two experimental groups on day 35 pi
(Fig. 5a, b). Nevertheless, 2-AG administration boosted microglial
myelin phagocytosis to 100% of the cells by 42 dpi (Fig. 5c, d). Finally,
MBP phagocytosis by microglia was studied using Imaris software
(Fig. 5e), which showed a signiﬁcant decrease in the amount of MBP
internalized by microglia in TMEV mice at 42 dpi compared to 35 dpi
(Fig. 5f, g). Interestingly, 2-AG administration enhanced the amount of
MBP phagocytosed by microglia at 42 dpi (Fig. 5f, g: see the online
Videos of the 3D microglial surfaces with internalized MBP in TMEV-
Veh and TMEV-2-AG: Supplementary V1 and V2, respectively).
In an attempt to show the direct eﬀects of 2-AG on microglial
phagocytosis, we used in vitro functional approaches with human and
rat microglial cells. E. Coli-coated beads were employed to measure the
phagocytic capacity of human microglia in the presence or absence of 2-
AG (Fig. 6a). Exposure to 2-AG (1 nM, 24 h) signiﬁcantly enhanced
phagocytosis by human microglial cells (Fig. 6b). We then studied the
eﬀects of 2-AG on the expression of phagocytosis associated genes by
microglia obtained from post-natal rat brains. When 2-AG (1 nM) was
added to the culture media for 6 h, there was a signiﬁcant increase in
cd206, msr1, sirp1α and trem2 mRNA compared to control microglia,
without aﬀecting the expression of scarb1, lamp1 and lamp2 (Fig. 6c).
These eﬀects were temporary and 24 h after 2-AG exposure, only trem2
remained signiﬁcantly upregulated (Fig. 6d). To approximate our in
vitro results to those obtained in our model of demyelination we pur-
iﬁed myelin from the adult rat brain and added it to microglia cultures
to assess whether 2-AG treated microglia (1 nM, 24 h) also improved
the expression of phagocytosis associated genes in the presence of
myelin, as well as to assess myelin phagocytosis itself. RT-PCR analysis
showed that when myelin was present in the culture medium for 6 h,
the cd206, msr1 and lamp1 gene expression augmented in 2-AG-treated
microglia relative to vehicle treated cells (Fig. 6e). Indeed, 2-AG pre-
treatment for 24 h improved the proportion of microglia that phago-
cytosed MBP+ myelin over 1 h, achieving the same eﬀect as the pro-
phagocytic factor, TGF-β. Nevertheless, no additive eﬀects were found
when 2-AG and TGF-β were added together (Fig. 6f). In fact, the
maximal level of microglial phagocytosis was reached 2 h after myelin
addition to the culture media. Given that the phagocytic index of mi-
croglia stimulated with 2-AG was the same as that seen after stimula-
tion with TGF-β (Fig. 6g), we analyzed the Cy3-labeled myelin inter-
nalized by microglia after 1 h when cells were pre-treated with 2-AG for
24 h in the presence of selective antagonists of CB1 and CB2 receptors.
A signiﬁcant increase in the area of myelin internalized by microglia
was elicited by 2-AG exposure, with the involvement of both CB1 and
CB2 receptors in this pro-phagocytic response (Fig. 6h, i). Previously,
we had found that microglia derived from CB2−/− deﬁcient mice di-
minished their phagocytic capacity (Mecha et al., 2015).
3.4. 2-AG restores the myelin content and myelin sheath thickness
Consistent with our earlier observations, the demyelinated corpus
callosum of TMEV mice shows a prominent increase in the labeling of
the myelin markers, MBP and PLP at 60 dpi (Fig. 7a, c). Although this
increase reaches 60% of the myelin content of Sham mice, it is en-
hanced notably, to 100%, when TMEV mice were administered 2-AG
from 28 to 42 dpi, stressing the positive eﬀects of this eCB in the re-
myelination process (Fig. 7b, d). Indeed, there was a strong relationship
between the increase in MBP or PLP staining and the increased myelin
sheath thickness at the ultrastructural level in mice that received 2-AG
(Fig. 7e). When analyzing the g-Ratio (the ratio of axon diameter to the
outer diameter of the myelin sheath), we found that it was lower in
mice administered 2-AG than in those that received the vehicle alone.
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Hence, a thicker myelin sheath formed around the small caliber axons
analyzed (Fig. 7f, g). The reparative eﬀects of 2-AG were also evident in
the total number of mature oligodendrocytes and progenitors, which
were both signiﬁcantly higher in the animals that received the eCB
(Fig. 7h). Finally, the number of microglia and their reactivity was
signiﬁcantly higher in TMEV mice, whereas both these parameters were
dampened in mice administered 2-AG, reaching the levels in Sham mice
(Fig. 7i). This phenomenon was probably related to the restoration of
homeostasis subsequent to complete remyelination.
4. Discussion
Understanding the mechanisms that orchestrate remyelination is
essential to develop eﬀective therapeutic strategies in MS. Besides the
presence of functional intact axons, successful remyelination requires
the timely migration of OPCs into the demyelinated lesion (Harlow
et al., 2015), inﬂammation-dependent OPC activation to drive their
diﬀerentiation into myelinating oligodendrocytes (Miron et al., 2011),
and the eﬀective removal of myelin debris by phagocytes (Baer et al.,
2009). Therefore, it has been hypothesized that the failure to undergo
remyelination in MS might be due to a temporal discordance between
OPC migration into the lesion, and the inﬂammation required for OPC
activation and diﬀerentiation provoked by myelin breakdown (Miron
et al., 2011). In the present study, we used the TMEV-IDD viral model of
MS to analyze the dynamics of remyelination in the corpus callosum. In
the preclinical phase of this model, there was prominent demyelination
in the corpus callosum 35 days after TMEV infection, which was fol-
lowed by spontaneous remyelination evident at 60 dpi (Mecha et al.,
2013b). Compared to uninfected mice, the dynamics of demyelination/
remyelination in TMEV animals constituted 5% of the total MBP
staining in the corpus callosum at 35 dpi, increasing to 12% of the area
occupied by MBP staining at 42 dpi, and ﬁnally, to 60% of the MBP and
PLP immunostaining by 60 dpi. We therefore focused on these three
time points – 35, 42 and 60 dpi – to study the mechanisms underlying
corpus callosum remyelination in the TMEV-IDD model.
First, we found that corpus callosum demyelination at 35 dpi was
accompanied by a decrease in MBP and PLP gene expression but not by
a loss of mature oligodendrocytes. Nevertheless, the number of OPCs
increased in the corpus callosum at this time, together with reduced
Olig-2 expression that is presumably due to OPC maturation (Mei et al.,
2013). To rule out the possibility of OPC recruitment from nearby re-
gions, we analyzed the number of progenitors in the adjacent cerebral
cortex and no diﬀerences were found between TMEV and Sham mice,
suggesting that the demyelinated area is repopulated by OPCs derived
from local, proliferating OPCs. However, we previously failed to ﬁnd
more proliferating NG2+ OPCs at 35 dpi or changes in their mor-
phology (Mecha et al., 2013a). Thus, it is likely that the acute in-
ﬂammation that provokes demyelination in the corpus callosum fol-
lowing TMEV infection provides the local stimulus for OPC
proliferation in the early stages of the model. Furthermore, and since
activation of the subventricular zone has been found at this time
(Mecha et al., 2013a), the contribution of subventricular progenitors to
remyelination in the corpus callosum still needs to be clariﬁed.
Oligodendrocyte recruitment and diﬀerentiation is regulated by
numerous environmental factors, including cytokines, chemokines, se-
maphorins and growth factors among others (Plemel et al., 2017). In
particular, the balance between Sema3A (chemorepellent for OPCs) and
Sema3F (an attractive migratory cue for OPCs) is one of the elements
that seems to be dysregulated in MS lesions, with increased Sema3A
expression apparently blocking OPC recruitment (Boyd et al., 2013).
Here, we found that both chemoattractant and chemorepellent cues
were downregulated at the mRNA level in the demyelinated corpus
callosum at 35 dpi, together with reduced cxcl-12 gene expression, a
potent chemoattractant implicated in OPC recruitment for remyelina-
tion (Patel and Klein, 2011).
In terms of microglia, we found more microglial cells in the corpus
callosum and adjacent cortex at 35 dpi, with no apparent changes in
their reactivity. Microglial cells are considered among the most versa-
tile cells owing to their capacity to adapt to their ever changing mi-
croenvironment. Microglia produce and respond to anti-inﬂammatory
cytokines like IL-10, inducing neuroprotective (Streit et al., 2005;
Hanisch and Kettenmann, 2007) and oligoprotective eﬀects (Molina-
Holgado et al., 2001). Indeed, IL-10 has been implicated in the induc-
tion of an acquired-deactivation state related to debris scavenging, and
in the pro-healing activity of microglia. The selective increase in il-10
gene expression in the demyelinated corpus callosum of TMEV mice
might be associated to the homeostatic responses to damage that are
designed to: i) maintain microglia in a deactivated state and avoid the
deleterious eﬀects of excessive inﬂammation; and ii) promote repair by
protecting the repopulating OPCs from damage.
The expression of genes responsible for the synthesis and degrada-
tion of the two main eCBs is weaker in the demyelinated corpus cal-
losum at 35 dpi, although the increase in MBP immunostaining suggests
this mRNA expression recovers at 42 dpi when the process of re-
myelination appears to have started in TMEV-IDD. In the cuprizone
model of demyelination elevated transcripts and protein levels of hy-
drolysis enzymes of 2-AG, MAGL, ABHD6 and ABHD12 have been ob-
served in corpus callosum without changes in 2-AG levels (Manterola
et al., 2018). In this respect, many discrepancies have been reported on
the levels of eCBs in the EAE model of MS when the immunized animals
were rats or mice. In rats, 2-AG and AEA were found to be diminished in
several areas of the CNS in acute EAE whereas mice showed increased
synthesis and decreased degradation provoking elevated levels of AEA
in the brains of EAE mice in the acute phase of the disease (Centonze
et al., 2007); this last work also found increased AEA levels in the CSF
of relapsing MS patients. Though positive and negative changes in eCBs
levels have been reported to occur in the same pathological condition
with both protective and worsening eﬀects (Di Marzo et al., 2004;
Pacher et al., 2006), cumulative evidence sustains the view of the ef-
ﬁcacy of eCB signaling to control neuroinﬂammation (Walter and
Stella, 2004). Even though we did not measure the levels of 2-AG and
AEA in the corpus callosum, the reduced gene expression of the ma-
chinery implicated in the synthesis and degradation of eCBs may be
presumptive of an overall reduction in their bioavailable levels at day
35 pi, whereas at day 42 pi the recovered metabolic eCBs enzymes
suggest re-established levels of these bioactive lipids likely associated
with their homeostatic and reparative roles. As such, it seems rational
to administer 2-AG before day 35 in order to investigate how exogenous
2-AG may inﬂuence endogenous remyelination. Although 2-AG ad-
ministration did not alter markers of myelin, or the number of mature
oligodendrocytes, OPCs or microglia countings in the corpus callosum
at 35 dpi, it was observed stronger microglial immunoreactivity. Even
in absence of proteins measurement, the RT-PCR data with upregulated
tnf-α and il-1β, in conjunction with increased il-10 suggest augmented
inﬂammatory mediators as a result of microglia activation. Given that
TMEV mice show a spontaneous activation of microglia at 42 dpi, likely
related to the uncoupling of inﬂammation after the onset of re-
myelination, we think that 2-AG prompts a moderate inﬂammatory
response at 35 dpi in the damaged corpus callosum but not in adjacent
cortical areas. In the acute phase of TMEV-IDD model, pro-in-
ﬂammatory cytokine genes are upregulated 100 times compared to
uninfected Sham mice (Mecha et al., 2018). Taking into account this
Fig. 4. Expression of phagocytosis associated genes at 35 and 42 dpi in the CC. RT-PCR at 35 and 42 dpi to study the expression of the myelin phagocytosis genes
sirp1α and cd47 (a, d), molecules functionally involved in the general phagocytic machinery (b, e) and lysosome-associated membrane proteins involved in pha-
gosome assembly (c, f). Each point represents the mean ± SEM from 10 mice per group: *p adjusted ≤0.03; **p≤ 0.01; ***p≤ 0.001 vs. Sham mice.
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Fig. 5. 2-AG improves myelin debris clearance by microglia following demyelination in the corpus callosum. Orthogonal views of triple Iba-1/MBP/DAPI im-
munoﬂuorescence at 35 (a) and 42 (c) dpi in the corpus callosum, revealing myelin phagocytosis by microglia. The proportion of microglia with internalized MBP
was quantiﬁed in confocal projections of the immunoﬂuorescence images. No diﬀerences can be found between the two experimental groups at 35 dpi (b); yet 2-AG
treatment improves the proportion of these phagocytic cells to 100% at 42 dpi (d). Imaris software was used to analyze the volume of the MBP inside the microglia,
and representative snapshots of the surfaces created for both Iba-1 and MBP are shown (e). Quantiﬁcation of the total volume of MBP per microglia cell (f), as well as
the volume of MBP relative to the volume of microglia (g), shows that MBP internalization in Vehicle-treated mice decreases at 42 dpi but it improves in those
animals that were treated with 2-AG. Each point represents the mean ± SEM from 3 mice per group: *p≤ 0.05 vs. Sham mice; #p≤ 0.05, ##p≤ 0.01; ###p≤ 0.001
vs. TMEV+Veh. Scale bar: 10 μm (a c) and 5 μm (e).
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strong increment in pro-inﬂammatory mRNA levels in response to the
viral infection, we take on that the 2–4 fold up-regulation of tnf-α, il-1β
and il-10 that we have found here suggests a mild inﬂammation. In-
deed, the spontaneous remyelination that ensued in the corpus cal-
losum of vehicle-TMEV animals did not reach the levels seen in Sham
mice, with only partial immunostaining of the myelin proteins MBP and
PLP, and a higher than normal g-Ratio in the adult corpus callosum
(estimated to average 0.75: Bercury et al., 2014). Notably, the myelin
immunostaining in 2-AG- treated TMEV mice coupled to the lower g-
Ratio at 60 dpi suggests that administering this eCB engages in-
ﬂammation to OPC diﬀerentiation, and that, 2-AG thereby enhances
spontaneous remyelination. The number of mature oligodendrocytes
(caption on next page)
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and OPCs also augments at 60 dpi relative to the vehicle TMEV mice.
Hence, the direct eﬀects of 2-AG on OPCs should be taken in con-
sideration given that 2-AG promotes their proliferation (Gomez et al.,
2015), survival and diﬀerentiation in vitro (Gomez et al., 2010, 2011).
The beneﬁcial role of neuroinﬂammation in the reparative processes
that take place in the CNS has been masked by the unquestionable
immune-mediated pathology of MS and its animal models. The im-
portance of microglia in remyelination can be summarized through
three key eﬀects: (i) the recruitment of progenitors, including stem cell
populations; (ii) the secretion of cytokines, chemokines, growth factors
and soluble mediators; and (iii) the eﬃcient removal of debris at the
lesion site (Napoli and Neumann, 2010). In the present work we found
that corpus callosum demyelination was associated with OPC re-
population and it was followed by delayed microglial activation. De-
myelination could be aﬀecting the synthesis of pro-inﬂammatory cy-
tokines, chemokines and growth factors as well as the eCB metabolic
machinery. The relevance of TNFα and IL-1β in remyelination is sup-
ported by studies that show that the absence of these cytokines sig-
niﬁcantly delays remyelination (Arnett et al., 2001; Mason et al., 2001).
These classical pro-inﬂammatory cytokines, together with CCL-2, can
be synthesized by activated OPCs to enhance OPC mobilization into
demyelinated areas (Moyon et al., 2015). Moreover, the reparative ef-
fects of TNF-α and IL-1β might be indirectly mediated by secondary
mechanisms, since BDNF expression by astrocytes seems to be TNF-α
dependent (Saha et al., 2006), and microglia and macrophages in IL-1β
deﬁcient mice fail to produce IGF-1 (Mason et al., 2001). In our study,
the onset of remyelination in the corpus callosum of TMEV mice at
42 dpi was associated with increased tnf-α and il-1β gene expression,
and that of igf-1, along with reduced bdnf gene expression, although this
last change was counteracted and upregulated by 2-AG administration.
Despite growth factors including BDNF promote oligodendrocyte dif-
ferentiation and MBP expression (Dubois-Dalcq and Murray, 2000;
Khorshidahmad et al., 2016) we cannot ensure that the eﬀect of 2-AG
on bdnf gene is contributing to the remyelination process that occurs in
the corpus callosum. It is well established that long-term inﬂammation
can be cytotoxic to OPCs (Setzu et al., 2006; Blakemore and Irvine,
2008) but the promoted microglia activation by 2-AG was followed in
our study by a restoration of homeostasis, speciﬁcally in terms of the
number and reactivity of microglia in the corpus callosum at 60 dpi,
when complete remyelination was achieved.
Myelin debris is thought to impair remyelination and inhibit OPC
diﬀerentiation (Kotter et al., 2006). Myelin contains inhibitory mole-
cules that help establish a non-permissive environment (David and
Lacroix, 2003; Schwab et al., 2005). Moreover, the direct contact of
OPCs with CNS myelin inhibits their maturation in a concentration-
dependent manner (Robinson and Miller, 1999). Indeed, blocking the
clearance of myelin debris by microglia impairs remyelination
(Lampron et al., 2015), such that an eﬀective phagocytic response is
needed after lesion for remyelination to occur. We found that there was
a decrease in the expression of sirp1α/cd47 in the demyelinated corpus
callosum at 35 dpi, although this was subsequently restored to control
levels at the onset of remyelination (42 dpi). It is likely that these
changes are related to a speciﬁc increase in the phagocytosis of myelin
debris following demyelination. The expression of phagocytosis
associated genes was found to be quite variable, with less mgf-e8 mRNA
detected at 35 dpi, followed by an upregulation at 42 dpi. This could be
related to the constant proportion of microglia with internalized MBP
between the two time points, and a smaller volume of MBP phagocy-
tosed at day 42 compared to 35 dpi.
The administration of 2-AG enhanced the expression of msr1 at
35 dpi and lamp1 at 42 dpi. We speculate that the mild changes of the
phagocytic machinery following 2-AG treatment may be associated
with intracellular myelin processing, as the aforementioned changes
were accompanied by a boost in the proportion of microglial cells with
internalized myelin from 35 to 42 dpi, together with the maintenance in
the volume of MBP phagocytosed. Together, the in vivo analysis of
phagocytosis suggests that 2-AG facilitated the clearance of myelin
debris. In addition, 2-AG targeting rodent microglia cultures not only
enhanced non-speciﬁc phagocytosis and the expression of most of the
phagocytosis associated genes but also, the phagocytic capacity of
puriﬁed myelin, augmenting myelin phagocytosis via the CB1 and CB2
cannabinoid receptors. This in vitro pro-phagocytic response of micro-
glia to 2-AG might be related to the acquisition of an alternative acti-
vation state of microglia due to their own 2-AG synthesis. However,
neither the balance between nos-II/arg-1 genes nor their im-
munostaining was altered in the corpus callosum at 42 dpi. NOS-II and
Arg-1 are two of the main markers used to identify classic and alter-
natively activated microglia, respectively (Mecha et al., 2015, 2018).
The observation that cultured human microglia also enhances phago-
cytosis by 2-AG call into question the extent to which this ﬁnding is
translatable to human microglia in vivo. The identity of the local cues
from microenvironment that govern and shape microglia in the human
adult brain remain largely unknown and constitutes an interesting ﬁeld
for future research.
We suggest that the modulation of microglia by 2-AG helps to es-
tablish the appropriate cellular and molecular milieu for OPCs thereby
facilitating diﬀerentiation and the eﬀective ensheathing of axons. This
appropriate milieu includes moderate mRNA levels of pro-in-
ﬂammatory cytokines, selective chemokines and growth factors, al-
though their protein amounts should be assessed to verify this as-
sumption. Indeed, alternatively activated microglia and macrophages
drive OPC diﬀerentiation during remyelination when demyelination of
the corpus callosum was induced by lysolecithin (Miron et al., 2013).
Additional beneﬁcial eﬀects of enhanced eCB signaling should also be
taken into account in our pathological paradigm, producing extensively
documented anti-oxidant, anti-excitotoxic and neuroprotective eﬀects
that will also aﬀect remyelination (Walter and Stella, 2004; Chiurchiú
et al., 2018; Paloczi et al., 2017; Fernández-Ruiz et al., 2015).
Irrespective of the immunological processes that lead to demyeli-
nation, myelin debris is generated and must be eﬃciently removed to
guarantee eﬀective remyelination. The temporal discordance between
OPC repopulation and the inﬂammation required for OPC activation
leads to unsuccessful repair and thus, treatments designed to facilitate
eﬃcient remyelination would be predicted to protect neurons from
axon degeneration, ameliorating subsequent clinical disability.
Experimental models of demyelination have enabled factors that in-
ﬂuence remyelination to be characterized. Consequently, some pro-re-
myelinating therapies have been tested in randomized controlled
Fig. 6. 2-AG boosts microglial phagocytosis in vitro. A non-speciﬁc phagocytosis challenge, using E. coli coated-beads in control and 2-AG treated human microglia
(a), shows that 2-AG (1 nM) treatment for 24 h signiﬁcantly increases the internalization of these beads (b). RT-PCR analysis showing the enhanced expression of
phagocytosis associated genes, cd206, msr-1, sirp1α and trem2 in rat microglia treated with 2-AG (1 nM) for 6 h (c) and trem2 for 24 h (d) relative to the vehicle-treated
cells (dashed lines). Myelin isolated from the adult rat CNS was added to the microglia cultures for 6 h (e), showing that 2-AG enhances the expression of the
phagocytosis associated genes, cd206, msr-1, and lamp1 compared to control microglia. The proportion of the phagocytic microglia/ﬁeld was also analyzed by
immunocytochemistry 1 and 2 h after the addition of puriﬁed myelin for 24 h (f), in the presence of 2-AG (1 nM), TGF-β (20 ng/ml) or both, showing a temporary
phagocytic response that is promoted by 2-AG and TGF-β administration. (g) No diﬀerences are found between microglia administered 2-AG and TGF-β when
analyzing the phagocytic index of the cells. (h) The quantiﬁcation of the Cy3-myelin internalized by microglia after 1 h of stimulation (i) shows a signiﬁcant increase
in myelin phagocytosis by 2-AG pretreatment via CB1 and CB2 receptors. Each point represents the mean ± SEM from: 4 microphotographs in 5 ﬁelds for human
microglia (*p≤ 0.05 vs. control); three to four independent experiments for RT-PCR studies (*p≤ 0.05; **p≤ 0.01, ***p≤ 0.001 vs control); four independent
experiments for the phagocytosis assay (**p≤ 0.01, ***p≤ 0.001 vs control; #p≤ 0.05 vs. 2-AG, ###p≤ 0.001 vs. control at 1 h). Scale bar: 50 μm (a); 25 μm (i).
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clinical trials, reporting some potential beneﬁts (reviewed in Stangel
et al. (2017)). The high expectations of these treatments contrast with
the diﬃculty in accurately detecting demyelination and remyelination
in patients using standard imaging technologies (Harlow et al., 2015).
We propose that 2-AG administration couples OPC diﬀerentiation to the
promotion of a beneﬁcial microglial response that improved clearance
of myelin debris, targeting multiple components of the myelination
cascade. The results presented highlight the importance of integrating
or engaging inﬂammatory and regenerative responses during the
complex process of remyelination in future MS treatment paradigms.
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